CX3CL1 and B-cell chronic lymphocytic leukemia: This may explain why CLL-related monocytes and healthy donor monocytes responded differently to KAND567, as well as why blocking the MAPK/ERK pathway is also involved in the downstream signaling of CX3CL1/CX3CR1 and monocyte survival [35,36].